Literature DB >> 27930371

Effect of Low-Concentration, Nonmydriatic Selective Alpha-Adrenergic Agonist Eyedrops on Upper Eyelid Position.

Taís B Mendonça1, Atauíne P Lummertz, Francisco J L Bocaccio, Fernando Procianoy.   

Abstract

BACKGROUND: Ptosis after botulinum toxin injection is a disturbing complication. Decongestant and antiglaucoma eyedrops are frequently prescribed for temporary improvement of eyelid ptosis. Although frequently cited on informal communications, the effect of these drugs on eyelid position has never been compared in a formal study.
OBJECTIVE: To measure the effect of low-concentration, nonmydriatic selective alpha agonist eyedrops on upper eyelid position. METHODS AND MATERIALS: This nonrandomized clinical trial enrolled 20 healthy subjects aged 18 to 50 years. The upper margin-reflex distance (MRD1) was measured before, 30, 60, and 120 minutes after administration of 1 drop of brimonidine 0.2%, phenylephrine 0.12%, or naphazoline 0.05% to the left eye.
RESULTS: There was no statistically significant difference in mean MRD1 between the brimonidine and phenylephrine groups when comparing baseline to all other study time points. After administration of naphazoline 0.05%, MRD1 had a mean increase of 0.56 ± 0.11 mm (p < 0.001) after 30 minutes, 0.47 ± 0.12 mm (p = 0.001) after 60 minutes, and 0.26 ± 0.09 mm (p = 0.028) after 120 minutes when compared with baseline.
CONCLUSION: Brimonidine 0.2% and phenylephrine 0.12% have no effect on eyelid aperture, but naphazoline 0.05% eyedrops could be useful for temporary relief of upper eyelid ptosis in selected patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27930371     DOI: 10.1097/DSS.0000000000000967

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  4 in total

Review 1.  A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options.

Authors:  Jason Bacharach; Wendy W Lee; Andrew R Harrison; Thomas F Freddo
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

2.  Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Authors:  David L Wirta; Michael S Korenfeld; Shane Foster; Robert Smyth-Medina; Jason Bacharach; Shane R Kannarr; Mark J Jaros; Charles B Slonim
Journal:  Clin Ophthalmol       Date:  2021-10-08

3.  Eyelid ptosis following botulinum toxin injection treated with briminodine 0.33% topical gel.

Authors:  Ghadah F Alotaibi; Sara F Alsukait; Hanan H Alsalman; Mohammed G Turkmani
Journal:  JAAD Case Rep       Date:  2022-01-31

Review 4.  Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options.

Authors:  Mark S Nestor; Haowei Han; Anita Gade; Daniel Fischer; Yves Saban; Roberto Polselli
Journal:  J Cosmet Dermatol       Date:  2021-08-11       Impact factor: 2.189

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.